{
  "schemaVersion": 1,
  "id": "research-363",
  "slug": "363-why-the-earlier-mash-trial-examined-liver-tissue-directly",
  "title": "Why the earlier MASH trial examined liver tissue directly",
  "catalogLabel": "Survodutide",
  "productCollection": "https://heritagebiolabs.com/research-library/products/survodutide",
  "productHandles": [
    "survodutide-700"
  ],
  "productUrls": [
    "https://heritagebiolabs.com/product/survodutide-700"
  ],
  "readingFocus": "Study findings",
  "readingFocusNote": "Reading focus is a navigational tag, not an evidence grade.",
  "wordCount": 350,
  "sourceYears": [
    2024,
    2026
  ],
  "paragraphs": [
    "A peptide is a short chain of amino acids connected by peptide bonds. Its sequence can help it engage receptors and affect metabolic signals. Survodutide is an investigational peptide with activity at the glucagon and GLP-1 receptors. The older direct study for the biopsy question was a phase 2 trial in adults with confirmed metabolic dysfunction-associated steatohepatitis, or MASH, and varying degrees of scarring. [1]",
    "The investigators used a biopsy to examine samples of liver tissue. That let them assess features of MASH and fibrosis, which means scarring, under a microscope. The primary outcome combined two conditions. The appearance of MASH had to improve, and the appearance of fibrosis could not get worse. This design accounts for the possibility that different features of liver disease can change in different directions. [1]",
    "The trial reported that 43% to 62% of participants in the active groups met that combined endpoint, depending on the group, compared with 14% in the placebo group. Improvement in fibrosis by at least one stage was reported separately and occurred in about one third of participants in the active groups and about one fifth in the placebo group. The two outcomes capture different changes. An improvement in MASH with stable fibrosis meets the first definition without meeting the second. [1]",
    "The trial also recorded adverse events. Nausea, diarrhea and vomiting were more frequent with survodutide than with placebo. The study involved a defined population, an investigational product and follow-up of 48 weeks. It gives information about tissue changes under those conditions and about adverse events that were observed during that period. [1]",
    "The newer SYNCHRONIZE-MASLD trial measured a reduction in liver fat by MRI and enrolled people identified by noninvasive tests or biopsy. That study addresses a different primary liver measure. The older phase 2 biopsy comparison remains directly relevant when the question is what the investigators saw in tissue. Neither a biopsy response over 48 weeks nor a change in MRI fat fraction alone can show how often later clinical complications occur. Longer studies that count those outcomes have their own role in the evidence. [1, 2]"
  ],
  "sources": [
    {
      "number": 1,
      "citation": "Arun J. Sanyal et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England Journal of Medicine (publication 2024-06-07).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/38847460/"
    },
    {
      "number": 2,
      "citation": "Lee M. Kaplan et al. Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial. Nature Medicine (publication 2026-06-07).",
      "url": "https://pubmed.ncbi.nlm.nih.gov/42252333/"
    }
  ],
  "canonicalUrl": "https://heritagebiolabs.com/research-library/articles/363-why-the-earlier-mash-trial-examined-liver-tissue-directly",
  "markdownUrl": "https://heritagebiolabs.com/research-library/data/articles/363-why-the-earlier-mash-trial-examined-liver-tissue-directly.md",
  "jsonUrl": "https://heritagebiolabs.com/research-library/data/articles/363-why-the-earlier-mash-trial-examined-liver-tissue-directly.json",
  "provenance": {
    "sourceArchive": "Peptide Research Articles - All 82 Volumes.zip",
    "sourceArchiveSha256": "9796bec477cbe2f8017dda81c7e58260985a13bdda1f934e8eb8d0549c2cada5",
    "sourceVolume": "Peptide Research Articles 073 - Survodutide and TB-500.docx",
    "sourceArticleNumber": 363,
    "contentSha256": "9edb4652548392a836fe3edbb73cd49b4c50ec70bf216ed819df8c4352829511",
    "statement": "Article titles, body paragraphs and numbered citations extracted without rewriting from owner-supplied Word volumes. Product mappings use exact catalog labels; reading-focus tags and excerpts are navigational metadata. No independent peer-review or comprehensive source verification is claimed."
  },
  "scope": "Educational article about published research. For research use only; not medical advice. Literature does not establish the identity, purity or activity of a purchased lot, and studies of individual components do not validate a blend."
}
